pi3k inhibitor Clinical Research Trials | TrialX

Loading...

Please select a valid location from the dropdown

Filter By

Clear all Advanced

Advanced Filters

Gender
Phase
Study Type
Sponsors
Accepts healthy volunteers
Online Trials
Age Group

Any (1)

Phase 1 (1)

Interventional (1)

Big Ten Cancer Research Consortium (1)

No (1)

No (1)

Adult (18+) (1)

I am/have/had

I am/have/hadarrhythmia

I am/have/hadpsoriasis

I am/have/hadmalt

I am/have/hadthyroiditis

I am/have/hadvitiligo

I am/have/hadautograft

I am/have/hadalcoholic cirrhosis

I am/have/hadhepatitis

I am/have/hadstem cell transplant

I am/have/had12 lead electrocardiogram

I am/have/hadpulmonary disease

I am/have/hadcell transplantation

I am/have/hadinterstitial lung disease

I am/have/hadpd-l1

I am/have/hadangina

I am/have/hadhypothyroidism

I am/have/hadhair thinning

I am/have/hadflow cytometry

I am/have/hadautologous hematopoietic stem cell transplant

I am/have/hadlymphoma

added new label for I am/have/had

more

I am looking for

I am looking forendocrine therapy

I am looking forhba1c

I am looking fornivolumab

I am looking forcyp3a4 inducers

I am looking forcopanlisib

I am looking forimmunosuppressive agents

I am looking forprednisone

I am looking forhormone therapy

I am looking forcyp3a4 inhibitors

I am looking forpi3k inhibitor

I am looking forattenuated vaccines

I am looking forrituximab

I am looking forhepatitis b surface antigen

I am looking forcorticosteroids

added new label for I am looking for

more

Advanced Filters

Loading...

Found 1 clinical trials

We call this “infoimagery”. It is unique to every trial and is generated based on a trials specific data eg. therapeutic area, study type, phase etc. and the centerwatch system associates the information to a matching set of related symbols and icons.

What's this?

Phase 1
For Seniors
For adults
Recruiting in 10s
Interventional Study
all
Recruiting

Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor Copanlisib Given in Combination With the Immunotherapeutic Agents Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma

Patients with relapsed or refractory follicular or marginal zone lymphoma who have received at least one prior line of therapy will receive Copanlisib IV: day 1, 8, 15 every 28 days Nivolumab IV: Cycle 1 days 1 and 15; then day 1 only Rituximab IV: Cycle 1 days 1, 8, …

psoriasis

arrhythmia

malt

thyroiditis

vitiligo

0 views
19 Feb, 2024

Congrats! You have your own personal workspace now.

Learn more

© Copyright TrialX 2024 All rights reserved.